AIDS 2022

The world’s largest conference on HIV/AIDS, AIDS 2022, convened from July 27-August 2 in Montreal, Canada. Hosted by the International AIDS Society, this was 24th session of the conference and the first since the pandemic to offer in-person and virtual access.

AIDS 2022 launched at a pivotal moment in HIV prevention. The ability to deliver two new proven PrEP methods will determine conversations and decisions happening now. These decisions will impact policies and funding for products in the pipeline and programs to deliver what’s available today for HIV prevention. It’s time to sharpen the agenda for HIV prevention and global health equity. AIDS 2022 offered opportunities to engage in these conversations while getting up to date on the latest research, rollout, policy and advocacy.

Below AVAC find resources related to the conference overall and find key sessions on prevention.

For a full roundup from Montreal, read our blog post.

Resources

• AVAC’s Prevention Roadmap curated on all things prevention at AIDS2022. You can download it as a sortable spreadsheet or PDF.
• AVAC’s Research-to-Rollout Literacy Networking Zone outlined in-person and virtual programming. See the schedule.

Posters

• Advancing HIV Prevention Research in Pregnant and Lactating Populations (PLP): Priority Advocacy Objectives and Next Steps
• Blazing a trail for MPT counseling: Efforts to develop recommendations for the Dual Prevention Pill and reconcile inconsistent guidance for delivering PrEP and oral contraception
• The Pathway to Accelerating Access and Introduction of Injectable CAB for PrEP
• Shaping the implementation science agenda for injectable long-acting cabotegravir for PrEP: results from a workshop convened by the Biomedical Prevention Implementation Collaborative (BioPIC)

Panels, Satellites, Sessions and Workshops Featuring AVAC and Partners

Friday, July 29

• [Satellite] PrEP-ing for 2025: Why optimization and scale-up of the PrEP service and product mix is critical to addressing unmet PrEP need and supporting effective use towards 2030 HIV prevention goals
  7:45-8:45 EDT

  Highlighting exciting advances in PrEP delivery from using demedicalized, simplified and integrated services and person-centered care. PrEP users, implementers, advocates, and researchers discuss how speeding access to newer PrEP products in lower-middle-income countries will propel achievement of 2025 goals. (Slides available.)

• [Satellite] Experimental medicine clinical trials in Africa: considerations and community engagement
  14:45-16:15 EDT

  A look into ethical challenges and community perspectives when conducting experimental medicine trials for preventive HIV vaccines in Africa. It will explore ways of communicating and meaningfully engaging with communities about experimental medicine trials.

• [Satellite] Accessing long-acting HIV prevention and treatment innovations: Landscape, service delivery, and pathways to affordability
  16:30-18:00 EDT

  Bringing together key stakeholders from ministries of health, civil society, industry, communities, funders, implementers, and researchers to discuss the differentiated service delivery models that can be used to ensure the current toolkit of prevention and treatment options reach communities who are vulnerable to HIV and do not burden the healthcare system.

• [Satellite] What’s new in WHO guidelines: innovations, access and monitoring
  16:30-18:00 EDT

  Presentation of new WHO guidelines focusing on innovations, access and person-centered monitoring in HIV services, including the launch of recommendations on injectable PrEP.

• [Satellite] Next Generation PrEP: Science, policy, and community impact
  18:15-19:45 EDT

  How do clinical trials assess efficacy of new and still-needed experimental products, with highly effective options available to the public? This session explores the need to bring key stakeholders including communities, industry and regulators to questions such as: How do regulators approach groundbreaking new trial designs in HIV prevention? How do these trial designs affect patients in the trials and those that may benefit from candidate drugs?

Saturday, July 30

• [Symposium] Equitable roll out of health products: What will it take?
  14:15-15:15 EDT

  Discussing innovative strategies, collaborative partnerships and transparent processes that engage advocates, government agencies, policy makers, government and non-governmental funders, regulatory bodies and pharmaceutical companies and result in equitable access to new products, the key to achieving rapid and effective product rollout.

Sunday, July 31

• [Satellite] A new global Roadmap for combination HIV prevention. Intensified actions towards achieving UNAIDS 2025 targets
  8:00-9:00 EDT

  Launch of the Global Prevention Coalition’s new 2025 HIV Prevention Roadmap.

• [Workshop] Our next shot: Effectively delivering injectable cabotegravir for PrEP (in-person only)
  10:30-12:00 EDT

  Explore what is needed to ensure that introductory research and programmes are strategically designed, user-centered and appropriately resourced to support successful roll out of CAB for PrEP. Co-convened by MOSAIC and WHO in partnership with EpiC, RISE, CASPR and BioPIC. (Slides available.)

• [Satellite] Demand, delivery and data for decision-making: How market preparation for the Dual Prevention Pill is reimagining prevention programs for a future with MPTs
  17:45-19:15 EDT

  A discussion on how to practically align HIV and FP programs and services to deliver the dual prevention pill (DPP), a multi-purpose prevention technology (MPT) in development, combining oral contraception with oral PrEP. Watch the recording.

Monday, August 1

• [Satellite] What has COVID-19 changed in vaccine R&D and what remains to change for an HIV vaccine?
  17:45-19:15 EDT

  Will look at what lessons learnt from COVID-19 vaccine development can be applied to HIV vaccine development.